IAA
KROS icon

Ironsides Asset Advisors’s Keros Therapeutics KROS Stock Holding History

Ironsides Asset Advisors’s Portfolio KROS Stock Details KROS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-6,456
Closed -$255K – 95
2021
Q3 		$255K Hold
6,456
– – 0.08% 82
2021
Q2 		$274K Buy
+6,456
New +$350K 0.08% 82

Other funds holding KROS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $74.1B AUM 71.18% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.65B AUM 203.21% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Ironsides Asset Advisors's KROS Position: Q4 2021 in Review

Ironsides Asset Advisors sold out of Keros Therapeutics (KROS) in Q4 2021, closing a stake of 6,456 shares — an estimated $255K sold.

Ironsides Asset Advisors first reported a position in KROS in Q2 2021 and held it in 2 quarters. The position peaked at $274K in Q2 2021. 99 funds tracked by Wall St. Rank hold KROS as of Q4 2021.

  • Ironsides Asset Advisors reported no remaining Keros Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Ironsides Asset Advisors sold 6,456 Keros Therapeutics shares in Q4 2021, an estimated $255K.
  • Ironsides Asset Advisors first reported a position in Keros Therapeutics in Q2 2021 and held it in 2 quarters.
  • Ironsides Asset Advisors's Keros Therapeutics position peaked at $274K in Q2 2021.
  • 99 funds tracked by Wall St. Rank held Keros Therapeutics as of Q4 2021.

Based on Ironsides Asset Advisors's 13F filing for Q4 2021, filed 4 Feb 2022.